Naronapride

DB05542InvestigationalSmall molecule

Investigated for use/treatment in gastroesophageal reflux disease (GERD) and gastroparesis.

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 4
Curator reviewed
Primary indication: Investigated for use/treatment in gastroesophageal reflux disease (GERD) and gastroparesis.Curator reviewed
Formula / weight: C₂₇H₄₁ClN₄O₅ · 537.1 g/mol (avg)
Also known as: (3R)-1-AZABICYCLO(2.2.2)OCT-3-YL 6-((3S,4R)-4-((4-AMINO-5-CHLORO-2- METHOXYBENZOYL)AMINO)-3-METHOXYPIPERIDIN-1-YL)HEXANOATE · 1-PIPERIDINEHEXANOIC ACID, 4-((4-AMINO-5-CHLORO-2-METHOXYBENZOYL)AMINO)-3-METHOXY-, 1-AZABICYCLO(2.2.2)OCT-3-YL ESTER, (3S,4R)-
Code names: ATI-7505

Resolves to

Compound

Structure

InChIKeyVGDDOIZXGFJDRC-VJTSUQJLSA-NSMILESCO[C@H]1CN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1

Targets

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

680Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Naronapride, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.